ArticleRadiology case reports2025
Esophageal neuroendocrine carcinoma: A clinical perspective on a rare and challenging disease.
Article in Radiology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine carcinomas (NECs) of the esophagus are exceptionally rare, comprising only 0.04% of all neuroendocrine tumors. These malignancies can remain asymptomatic or manifest through digestive symptoms such as dysphagia and abdominal discomfort. Due to their rarity, limited studies exist, resulting in insufficient knowledge about their prognosis and treatment, with conflicting data in the literature. This report presents the case of a 62-year-old male chronic smoker with chronic dysphagia. Diagnostic evaluations, including gastroscopy and CT, revealed a circumferential lesion in the lower esophagus. Histopathological analysis confirmed a diagnosis of poorly differentiated large-cell neuroendocrine carcinoma. Esophageal NECs are aggressive and poorly understood tumors. Tumor size, lymph node involvement, and metastatic status are critical factors influencing treatment decisions. However, there are no established guidelines for their management. Extensive research is urgently needed to develop standardized treatment approaches and improve the prognosis of patients with high-grade esophageal NECs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.